FCMI
RGLS

Foresite Capital Management III’s Regulus Therapeutics RGLS Stock Holding History

Foresite Capital Management III’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,576
Closed -$5.47M – 21
2016
Q1 		$5.47M Buy
6,576
+584
+10% +$465K 4.23% 7
2015
Q4 		$6.27M Buy
+5,992
New +$6.01M 5.56% 7

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management III's RGLS Position: Q2 2016 in Review

Foresite Capital Management III sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 6,576 shares — an estimated $5.47M sold.

Foresite Capital Management III first reported a position in RGLS in Q4 2015 and held it in 2 quarters. The position peaked at $6.27M in Q4 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Foresite Capital Management III reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Foresite Capital Management III sold 6,576 Regulus Therapeutics shares in Q2 2016, an estimated $5.47M.
  • Foresite Capital Management III first reported a position in Regulus Therapeutics in Q4 2015 and held it in 2 quarters.
  • Foresite Capital Management III's Regulus Therapeutics position peaked at $6.27M in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Foresite Capital Management III's 13F filing for Q2 2016, filed 12 Aug 2016.